logo
logo
Sign in

Global Plasma Fractionation Market : leading key players

avatar
Sasha Sharma
Global Plasma Fractionation Market : leading key players

The plasma fractionation market is projected to reach USD 34.9 billion by 2024 from USD 25.4 billion in 2019, at a CAGR of 6.6% during the forecast period. The factors such as the growing use of immunoglobulins in various therapeutic areas, increase in plasma collection (and the number of plasma collection centers), and the increasing use of alpha-1-antitrypsin are expected to drive the market during the forecast period.

 The plasma fractionation market is an oligopolistic market, with a few players accounting for a major share of the market. CSL (Australia), Grifols (Spain), Shire (Ireland), and Octapharma (Switzerland) are the major players dominating the market. Other prominent players in the market include Kedrion (Italy), Biotest (Germany), Sanquin (Netherlands), China Biologic Product, BPL (UK), Japan Blood Products Organization, Green Cross Corporation (South Korea), Shanghai RAAS Blood Products (China), Beijing Tiantan Biological Products (China) and Bharat Serums and Vaccines (India). Expansions and acquisition are the main strategies adopted by these players to strengthen their position in the market.

CSL

CSL dominates the plasma fractionation market. With distribution channels in over 30 countries and 200 plasma collection centers, CSL has established itself as a significant player in the plasma fractionation market. The company provides plasma-derived products for acute and chronic conditions such as hemophilia, Von Willebrand disease, and primary immune deficiencies.

Apart from North America, the company has a strong presence in Europe, Australia, and Asia. Its strong distribution network is spread across 30 countries and major facilities in Australia, Germany, Switzerland, and the US. This helps the company to make sure its products are available across the globe.

To Know More Download PDF Brochure: 
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=93798284

SHIRE

Shire held the second position in the plasma fractionation market in 2018, which can be attributed to its expertise in medical devices, pharmaceuticals, and biotechnology. Shire is a global biopharmaceutical company with a wide product portfolio for differentiated therapies to treat many rare diseases such as hemophilia, immune deficiencies, alpha-1 antitrypsin deficiency, and other chronic & acute medical conditions. The company has a strong presence in North America, Europe, the Middle East, Africa, Asia Pacific, and Latin America. Its wide geographic presence helps it to strengthen its market globally. To maintain its position in the market, the company focuses on developing new and innovative products. For instance, in November 2016, Baxalta, a subsidiary of Shire launched CUVITRU, a subcutaneous immunoglobulin (Human), in the US for primary immunodeficiency.

collect
0
avatar
Sasha Sharma
guide
Zupyak is the world’s largest content marketing community, with over 400 000 members and 3 million articles. Explore and get your content discovered.
Read more